PCM
LAB icon

Prelude Capital Management’s Standard BioTools LAB Stock Holding History

Prelude Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-48,468
Closed -$291K – 1697
2020
Q4 		$291K Buy
48,468
+25,100
+107% +$165K 0.01% 924
2020
Q3 		$174K Buy
+23,368
New +$161K 0.01% 727
2020
Q1 		– Sell
-920
Closed -$3K – 1756
2019
Q4 		$3K Sell
920
-160
-15% -$563 ﹤0.01% 1812
2019
Q3 		$5K Sell
1,080
-25,167
-96% -$198K ﹤0.01% 1565
2019
Q2 		$323K Buy
26,247
+24,735
+1,636% +$315K 0.02% 589
2019
Q1 		$20K Sell
1,512
-1,312
-46% -$13.8K ﹤0.01% 1316
2018
Q4 		$24K Buy
2,824
+586
+26% +$4.57K ﹤0.01% 1222
2018
Q3 		$17K Sell
2,238
-331
-13% -$2.35K ﹤0.01% 1343
2018
Q2 		$15K Sell
2,569
-2,142
-45% -$12.2K ﹤0.01% 1407
2018
Q1 		$28K Buy
4,711
+1,939
+70% +$12.7K ﹤0.01% 1213
2017
Q4 		$16K Sell
2,772
-2,823
-50% -$15.5K ﹤0.01% 1163
2017
Q3 		$28K Buy
5,595
+2,959
+112% +$12.4K ﹤0.01% 1246
2017
Q2 		$11K Buy
+2,636
New +$12.5K ﹤0.01% 1379
2016
Q3 		– Sell
-1,000
Closed -$9K – 1710
2016
Q2 		$9K Buy
+1,000
New +$9.4K ﹤0.01% 1398

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prelude Capital Management's LAB Position: Q1 2021 in Review

Prelude Capital Management sold out of Standard BioTools (LAB) in Q1 2021, closing a stake of 48,468 shares — an estimated $291K sold.

Prelude Capital Management first reported a position in LAB in Q2 2016 and held it in 14 quarters. The position peaked at $323K in Q2 2019. 138 funds tracked by Wall St. Rank hold LAB as of Q1 2021.

  • Prelude Capital Management reported no remaining Standard BioTools position as of Q1 2021 after selling out during the quarter.
  • Prelude Capital Management sold 48,468 Standard BioTools shares in Q1 2021, an estimated $291K.
  • Prelude Capital Management first reported a position in Standard BioTools in Q2 2016 and held it in 14 quarters.
  • Prelude Capital Management's Standard BioTools position peaked at $323K in Q2 2019.
  • 138 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.